Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors

Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining its leading cancer drug Opdivo (nivolumab) with ... Read More